We’d like to share all our latest news with you. Do get in touch if you’d like to talk to us about any of these stories, or if you have an exciting innovation of your own. Fold the Future Sibylla Biotech is developing a highly differentiated approach in the field of protein degradation. It is …
We’d like to share our latest news with you. Do get in touch if you’d like to talk to our Team about any of these stories, or if you have an exciting innovation of your own that you’d like to share with us.. LtoR: Joint founders of Palliare, Caroline Sherlock and John O’Dea, Dr Faraz Khan …
Welcome to Seroba’s May 2021 newsletter with all our latest news. PQ Bypass Sold to Endologix Seroba’s portfolio company, PQ Bypass, has been acquired by Endologix. PQ Bypass is a medical device pioneer advancing the treatment of complex peripheral artery disease (PAD). The company’s Detour 2 device, which was awarded Breakthrough Device designation by the …
Welcome to Seroba’s December 2020 newsletter with all our latest news. Fusion To Partner with AstraZeneca Fusion has announced a partnership with AstraZeneca to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Together, the companies will discover, develop and commercialize novel targeting therapies, which will utilize Fusion’s Fast-Clear™ linker technology …
Welcome to Seroba’s July 2020 newsletter with all the latest news from our portfolio. A Precision Exit Seroba’s portfolio company, PrecisionBiotics Group, has been acquired by Novozymes. Based in Cork, Ireland, PrecisionBiotics Group is a global pioneer in the field of probiotics for human gut health. Its products include the award-winning Alflorex for digestive health …
Welcome to Seroba’s November 2019 newsletter. In this issue we focus on science, entrepreneurship and funding for innovatiion. In the News – Endotronix Endotronix has been much in the news lately. The company closed an extended Series D financing round in October providing capital to fund the company to FDA approval. Read more. They also announced an …
Welcome to Seroba’s newsletter. In this issue we share news about some of the exciting things happening in our portfolio with a focus on exits and funding developments. Raising a Storm! Seroba has led a £14m investment into STORM Therapeutics, a leading biotech company focused on small molecule therapies modulating RNA modifying enzymes. This investment …
Welcome to Seroba’s newsletter. In this issue we share news about some of the exciting things happening in our portfolio and focus on exits and funding developments within the life sciences. Our Second Brain Most people have heard about the benefits of probiotics for our mental and physical health, but science is now discovering that …